Synthesis and Biological Evaluation of Spiroketal Derivatives

螺缩酮衍生物的合成及生物学评价

基本信息

项目摘要

Reveromycin A is a 6, 6-spiroketal antibiotic isolated from the genus Streptomyces and shows strong biological activities that makes it potentially useful as an antitumor drug based on inhibition of isoleucyl-tRNA synthetase. Reveromycin A is also expected as a therapeutic agent for hypercalcemia and bone disease. Spirofungins A and B are also polyketide-type antibiotics isolated from Streptomyces violaceusniger Tu 4113 as a mixture in the ratio of 4: 1 and show various antifungal activities, particularly against yeasts. Various derivatives of reveromycin A and spirofungin A, focusing on the 5S hydroxyl group and C18 hemisuccinyl group, were synthesized and their inhibitory effects on both the isoleucyl-tRNA synthetase activity and the survival of osteoclasts, and activities on the morphological reversion of src^<ts>-NRK cells were examined. It was found that 2, 3-dihydroreveromycin A, 4-hydrox3rreveromycin A and the 3, 5-dihydroxyl derivative are the promising derivative of reveromycin A based on the activity and stability. We have developed a novel method for the preparation of the succinates of tertiary alcohols for the synthesis of reveromycin A. 3-Butyn-1-ol was converted into a lactone in eleven steps. Oxidative cleavage of the dihydropyrans prepared via the palladium-catalyzed coupling of the ketene acetal triflates and zinc homoenolate with 0_s0_4-Pb (OAc) _4 gave the succinates of tertiary alcohols. Then, the succinates were converted into the 6, 6-spiketal via the coupling with an alkyne.
逆转霉素A是从链霉菌属中分离得到的一种6,6-螺酮类抗生素,具有很强的生物活性,可作为一种基于抑制异亮氨酰-tRNA合成酶的抗肿瘤药物。反转霉素A也有望成为治疗高钙血症和骨病的药物。螺旋菌素A和螺菌素B也是从紫色链霉菌Tu 4113中以4:1的比例分离出来的聚酮类抗生素,具有多种抗真菌活性,特别是对酵母菌。合成了以5S羟基和C18半琥珀酰基为侧重点的反转霉素A和螺旋霉素A的各种衍生物,考察了它们对破骨细胞异亮氨酰-tRNA合成酶活性和细胞存活的抑制作用,以及对src^&lt;ts&gt;-NRK细胞形态逆转的作用。从活性和稳定性来看,2,3-二氢逆转霉素A、4-羟基-3-逆转霉素A和3,5-二羟基衍生物是很有前途的逆转霉素A的衍生物。提出了一种新的合成反转霉素A的叔醇丁二酸酯的合成方法。3-丁基-1-醇经11步反应生成内酯。在钯的催化下,三氟缩酮缩醛和高烯醇锌与OSO4-Pb(OAc)4反应生成的二氢吡喃被氧化裂解,得到叔醇丁二酸酯。然后,丁二酸酯通过与炔的偶联反应转化为6,6-螺酮。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Synthesis and biological activities of reveromycin A and spirofungin A derivatives
  • DOI:
    10.1016/j.bmcl.2008.05.054
  • 发表时间:
    2008-07-01
  • 期刊:
  • 影响因子:
    2.7
  • 作者:
    Shimizu, Takeshi;Usui, Takeo;Sodeoka, Mikiko
  • 通讯作者:
    Sodeoka, Mikiko
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TAKESHI Shimizu其他文献

TAKESHI Shimizu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Arbeiten zur Optimierung der Hetero-Diels-Alder-Reaktion als alternative Synthesemethode zum Aufbau von Spiroketalen. Anwendung in der Totalsynthese von Spirofungin A.
致力于优化杂狄尔斯-阿尔德反应作为构建螺缩酮的替代合成方法。
  • 批准号:
    42144109
  • 财政年份:
    2007
  • 资助金额:
    $ 2.57万
  • 项目类别:
    Research Fellowships
Synthesis and Biological Evaluation of Antifungal Antibiotics, Spirofungin A and B
抗真菌抗生素螺芬净 A 和 B 的合成及生物学评价
  • 批准号:
    16590026
  • 财政年份:
    2004
  • 资助金额:
    $ 2.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了